ArticleJournal of the Pediatric Infectious Diseases Society2025
Streptococcal Serology Reference Intervals in an Australian Pediatric Cohort.
Article in Journal of the Pediatric Infectious Diseases Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDiagnostic criteria for acute rheumatic fever and post-streptococcal glomerulonephritis, the 2 major autoimmune complications of Streptococcus pyogenes infection, include serological evidence of preceding infection. The S. pyogenes proteins, namely streptolysin O and deoxyribonuclease B, are the most widely used targets for clinical streptococcal serology. We aimed to establish age-based reference intervals (RIs) for healthy children in Victoria, Australia, to guide interpretation of anti-streptolysin O (ASO) levels measured by turbidimetry and nephelometry, and anti-deoxyribonuclease B (ADB) levels by nephelometry.
methodsSerum samples were collected from healthy pediatric cohorts aged 32-week gestation to <18 years at 4 hospitals in Melbourne, Australia, between February 2015 and October 2018. Anti-streptolysin O levels were measured in 2 cohorts: by turbidimetry in cohort 1 and by nephelometry in cohort 2. Anti-deoxyribonuclease B levels were measured by nephelometry in cohort 2. Reference intervals (RIs) for each age group were generated, including 80% upper limit of normal (ULN) cut-offs.
resultsAnti-streptolysin O levels were measured by turbidimetry for 359 samples from cohort 1, and ASO and ADB levels were measured by nephelometry for 360 samples from cohort 2. Anti-streptolysin O levels, measured by turbidimetry, were highest in children 5-9 years of age (80% ULN 346 IU/mL) in cohort 1. For cohort 2, there was a linear age-related increase in ASO levels measured by nephelometry (80% ULN 426 IU/mL in those 15 to <18 years old) and ADB levels were highest in children aged 10-14 years (80% ULN 454 IU/mL).
conclusionsWe established age-specific RI for ASO and ADB levels measured by turbidimetry and nephelometry for healthy Australian children. This study highlights the importance of local method-specific age-based RI to interpret ASO and ADB levels when clinicians suspect acute rheumatic fever or post-streptococcal glomerulonephritis in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.